Table 4.
Less intensive front-line therapy for young fit patient with mantle cell lymphoma
| Regimen | Series | No. | Age (ys) Median (range) | MIPI Low/Int/High (%) | ORR (%) | CR (%) | mFU (ms) | mPFS (ms) | mOS (ms) | TRM (%) | Second malignancy(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R-CHOP | Howard (2002) [20] | 40 | 55 (31–69) | na | 96 | 48 | 25 | 16.5 | na | 2.5 | na |
| R-CHOP | LaCasce (2012) [26] | 29 | 55 (< 65) | 21/76/3 (IPI) | na | na | 33 | 18% 3-y PFS | 69% 3-y OS | 31 | na |
| R-CHOP Vs. CHOP |
Lenz (2005) [47] | 38 | < 65 | 28/66/7 a (IPI) | 94a | 34a | 18 | NRa | NRa | 2a | na |
| 39 | < 65 | 20/70/10a (IPI) | 75a | 7a | 18 | NRa | NRa | 0a | na | ||
| R-CHOP Vs. VR-CAP |
Robak(2015) [50] | 244 | 66(34–82) | 29/38/33 | 89 | 42 | 40 | 16.1 | 56.3 | 6 | na |
| 243 | 65(26–88) | 31/40/29 | 92 | 53 | 40 | 30.7 | NR | 5 | na | ||
| B-R + Ibrutinib | Maddocks(2015) [48] | 17 5 (untreated) | na (62–72) | na | 94 | 76 | na | NR | NR | na | na |
| R-CHOP+ Ibrutinib | Younes (2014) [49] | 5 | na | na | 94 (all subtypes) | 72 | 7.1 | na | na | na | na |
Abbreviations as indicated in the Table 1
Note: VR-CAP rituximab, cyclophosphamide, doxorubicin, bortezomib, prednisone, B-R bendamustine and rituximab
a including younger than 65 years and older than 65 years